NCT00591383UnknownPhase 1
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Alaunos Therapeutics
- Enrollment
- 10
- Primary Endpoint
- toxicities
Study Overview
Brief Summary
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with erlotinib is considered medically acceptable.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects with advanced, histologically confirmed solid tumors for which no standard therapy exists and for whom treatment with erlotinib is considered medically acceptable.
- •≥18 years of age
- •ECOG performance score ≤2
- •Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines. Measurable lesions MUST NOT have been in a previously irradiated field or injected with biological agents.
- •Life-expectancy ≥12 weeks
- •No more than 2 prior chemotherapy regimens for metastatic disease
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted <2 weeks prior to Study Day 1:
- •Creatinine ≤1.5×upper limit of normal (ULN) OR a calculated creatinine clearance ≥50 cc/min
- •Total bilirubin ≤1.5×ULN
- •Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5×ULN
- •White blood cell count ≥3.0×109/L
- •Absolute Neutrophil Count (ANC) ≥1.5×109/L
- •Platelets ≥100×109/L
- •Hemoglobin ≥10 g/dL
- •Written informed consent in compliance with ZIOPHARM policies and the Human Investigation Review Committee with jurisdiction over the site.
- •Each man and woman of childbearing potential must agree to use a reliable method of contraception during the study and for 3 months following the last dose of study drug.
Exclusion Criteria
- •New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months (see Appendix 5)
- •Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation
- •Subjects cannot be receiving cytochrome P450-inducing anticonvulsants (EIAEDs: eg, phenytoin, carbamazepine, phenobarbital, primidone, oxcarbezine)
- •Subjects may not be taking CYP3A4 inducers (rifampicin)
- •Subjects must not have any evidence of bleeding diathesis or coagulopathy
- •Subjects with international normalized ration (INR) >1.5 are excluded, unless the subject is on full dose warfarin
- •Subjects on full-dose anticoagulants (eg, warfarin) are eligible provided that both of the following criteria are met:
- •The subject has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
- •The subject has no active bleeding or pathological condition that carries a high risk of bleeding (eg, tumor involving major vessels or known varices.
- •Subjects on prophylactic anticoagulation (ie, low-dose warfarin) are eligible provided their coagulation parameter levels are as follows: prothrombin time (INR of prothrombin time) <1.1×institutional ULN
- •Pregnancy and/or lactation
- •Uncontrolled systemic infection (documented with microbiological studies)
- •Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry.
- •Prior treatment with EGFR inhibitors
- •Radiotherapy during the study or within 3 weeks of study entry
- •Surgery within 4 weeks of start of study drug excluding tumor biopsy for pharmacodynamic parameters
- •Investigational drug therapy outside of this trial during or within 4 weeks of study entry
- •History of an invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer
- •Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
- •Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance with the study protocol
Arms & Interventions
Single Arm
Experimental
Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
Intervention: indibulin (Drug)
Single Arm
Experimental
Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
Intervention: erlotinib (Drug)
Outcomes
Primary Outcomes
toxicities
Time Frame: 6 months
Secondary Outcomes
- pharmacokinetics(6 months)
Investigators
Similar Trials
Terminated
Phase 1
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationAdvanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene MutationERBB2 Gene AmplificationERBB2 Gene MutationERBB3 Gene MutationERBB4 Gene MutationKRAS Gene MutationMetastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmNCT03065387M.D. Anderson Cancer Center84
Unknown
Phase 3
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationNon-Small Cell Lung CancerNCT02001896Xinjiang Medical University60
Active, not recruiting
Not Applicable
Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer. - tarcevapancreasPatients with unresectable advanced or metastatic pancreatic cancerMedDRA version: 6.1Level: PTClassification code 10033609EUCTR2006-001238-41-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
Completed
Phase 1
Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancerJPRN-UMIN000001780West Japan Oncology Group60
Unknown
Phase 2
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung AdenocarcinomaCarcinoma, Non-Small-Cell LungNCT02146118MedicalLogic42